Clinical Scorecard: Creation and internal assessment of a nomogram tailored for lymphoma to forecast venous thromboembolism risk: analysis of a retrospective cohort comprising 790 patients

At a Glance

Key Highlights

• Thromboembolism occurs 4 to 7 times more frequently in cancer patients than in the general population.
• Incidence of thromboembolism in lymphoma patients varies from 4% to nearly 60%.
• The study identified 77 cases of thromboembolism (9.75%) among 790 lymphoma patients.
• Upper-limb venous thrombosis was the most common type of thromboembolism observed.
• The ThroLy score provides refined risk stratification for lymphoma patients.

Guideline-Based Recommendations

Diagnosis

• Utilize lymphoma-specific models for risk assessment, such as the ThroLy score.

Management

• Implement prophylaxis strategies based on identified risk factors.

Monitoring & Follow-up

• Regularly assess patients for signs of thromboembolism, especially post-chemotherapy.

Risks

• Monitor for increased morbidity and mortality associated with thromboembolism.

Patient & Prescribing Data

790 newly diagnosed lymphoma patients treated at a hematology department.

Thromboembolism risk varies with lymphoma subtype and treatment cycles.

Clinical Best Practices

• Incorporate disease-specific factors into thromboembolism risk assessments.
• Use a points-based clinical risk score for bedside decision-making.
• Conduct thorough assessments of comorbidities and treatment history.

References

• Study on Thromboembolism in Cancer Patients
• ThroLy Score Evaluation
• Khorana Score Limitations